Belantamab mafodotin (GSK2857916) is a BCMA-targeting antibody-drug conjugate for multiple myeloma research. It promotes immune cell activity within tumors and inhibits tumor progression, making it applicable for both in vitro mechanistic studies and in vivo xenograft models of hematological malignancies.
Concentration:
7.98 mg/mL
Molecular Weight:
146.06 kDa
Purity:
99.14% (May vary between batches)
CAS Number:
[2050232-20-5]
Target:
Antibody-Drug Conjugates (ADCs)
* VAT and and shipping costs not included. Errors and price changes excepted